I

INIFY Laboratories AB
OSE:INIFY

Watchlist Manager
INIFY Laboratories AB
OSE:INIFY
Watchlist
Price: 4.22 NOK 2.93% Market Closed
Market Cap: 333m NOK
Section:
 

Relative Value

The Relative Value of one INIFY stock under the Base Case scenario is hidden NOK. Compared to the current market price of 4.22 NOK, INIFY Laboratories AB is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INIFY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

742.8
P/S
P/S
Price to Sales
742.8
vs History
vs Industry
Median 3Y
1 172
Median 5Y
1 115.1
Industry
2.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-19.2
Industry
22.9
More Details
N/A
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
14.7
More Details
N/A
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
21.4
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
vs Industry
Median 3Y
4.9
Median 5Y
4.8
Industry
2.3
More Details
537.7
EV/S
EV/S
Enterprise Value to Sales
537.7
vs History
vs Industry
Median 3Y
967
Median 5Y
910.1
Industry
2.6
More Details
973.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
973.1
vs History
vs Industry
Median 3Y
1 749.9
Median 5Y
1 647
Industry
5.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-12.7
Median 5Y
-16.2
Industry
12.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.7
Median 5Y
-16.2
Industry
17.2
More Details
N/A
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
15
More Details
N/A
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
19
More Details
9.7
EV/IC
EV/IC
Enterprise Value to IC
9.7
vs History
vs Industry
Median 3Y
22.3
Median 5Y
21.1
Industry
1.9
More Details

Multiples Across Competitors

INIFY Competitors Multiples
INIFY Laboratories AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
INIFY Laboratories AB
OSE:INIFY
333m NOK 742.8 -7.8 -5.4 -5.4
US
CVS Health Corp
NYSE:CVS
102B USD 0.3 217.4 14.2 14.2
US
Cigna Corp
NYSE:CI
74.4B USD 0.3 12.1 7.8 9.9
US
Cigna Group
XMUN:CGN
64.7B EUR 0.3 12.3 7.9 10
DE
Fresenius SE & Co KGaA
XETRA:FRE
27.7B EUR 1.2 24.3 10.6 16
DE
Fresenius Medical Care AG
XMUN:FME
22.9B EUR 1.2 31.8 10.1 21.6
US
Laboratory Corporation of America Holdings
NYSE:LH
20.9B USD 1.5 24.4 13.3 18.6
US
Quest Diagnostics Inc
NYSE:DGX
19.4B USD 1.8 20.1 11.2 15.1
US
Guardant Health Inc
NASDAQ:GH
13.8B USD 15.3 -34.5 -36.4 -33
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.4B EUR 0.6 15.9 6.3 13.5
US
DaVita Inc
NYSE:DVA
7.9B USD 0.6 10.2 6.6 8.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
I
INIFY Laboratories AB
OSE:INIFY
Average EV/EBITDA: 9.8
Negative Multiple: -5.4 		N/A N/A
US
CVS Health Corp
NYSE:CVS
14.2
25%
0.6
US
Cigna Corp
NYSE:CI
7.8
5%
1.6
US
C
Cigna Group
XMUN:CGN
7.9
5%
1.6
DE
Fresenius SE & Co KGaA
XETRA:FRE
10.6
14%
0.8
DE
Fresenius Medical Care AG
XMUN:FME
10.1
10%
1
US
Laboratory Corporation of America Holdings
NYSE:LH
13.3
16%
0.8
US
Quest Diagnostics Inc
NYSE:DGX
11.2
8%
1.4
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -36.4 N/A N/A
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
6.3
10%
0.6
US
DaVita Inc
NYSE:DVA
6.6
4%
1.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
I
INIFY Laboratories AB
OSE:INIFY
Average EV/EBIT: 14.2
Negative Multiple: -5.4 		N/A N/A
US
CVS Health Corp
NYSE:CVS
14.2
19%
0.7
US
Cigna Corp
NYSE:CI
9.9
5%
2
US
C
Cigna Group
XMUN:CGN
10
5%
2
DE
Fresenius SE & Co KGaA
XETRA:FRE
16
20%
0.8
DE
Fresenius Medical Care AG
XMUN:FME
21.6
25%
0.9
US
Laboratory Corporation of America Holdings
NYSE:LH
18.6
27%
0.7
US
Quest Diagnostics Inc
NYSE:DGX
15.1
11%
1.4
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -33 N/A N/A
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13.5
25%
0.5
US
DaVita Inc
NYSE:DVA
8.9
4%
2.2

See Also

Summary
INIFY intrinsic value, competitors valuation, and company profile.
DCF Valuation
INIFY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INIFY stock valuation using valuation multiples.
Wall Street Estimates
INIFY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INIFY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.